GSK’s announcement that it will continue to invest in the UK has been hailed as important for the life‑sciences sector by Stevenage Bioscience Catalyst (SBC), the independent not‑for‑profit campus created in partnership with GSK, the Wellcome Trust and the UK Government.
Investment and local growth
SBC, launched in 2012 to nurture early‑stage life‑science companies, said it now hosts more than 45 businesses working across areas such as cell and gene therapy, AI‑enabled drug discovery, neuroscience, diagnostics and precision medicine. The organisation highlighted that companies based at the campus have together raised in excess of £4 billion in investment since its creation.
Those figures were presented alongside local ambitions. Stevenage Borough Council is engaged in a £1 billion regeneration programme for the town and describes the life‑science cluster as central to plans to boost innovation, attract investment and create high‑value employment.
What stakeholders said
The statement from SBC quoted its board chair and other civic leaders emphasising confidence in the cluster and the desire to broaden ties with other UK centres of excellence.
“It is good news for the economy and life sciences R&D that GSK are continuing to invest the UK,” said Professor Jackie Hunter, Chair of the Stevenage Bioscience Catalyst Board.
Professor Hunter noted the role the campus has played in building a local ecosystem that brings together entrepreneurs, scientists, investors and industry partners to speed the translation of research into medicines and technologies. Andrew Waters, Chief Executive Officer of SBC, referred to the uncertainty for colleagues affected by GSK’s announcement but reiterated the organisation’s commitment to supporting its community on campus.
Wider implications for the sector
The response from Stevenage underlines two national policy priorities. First, the importance of industry anchor investments in sustaining regional clusters where academic research, start‑ups and commercial players can collaborate. Second, the role of public and philanthropic partnerships—here involving government and the Wellcome Trust—in de‑risking early‑stage ventures and attracting follow‑on capital.
SBC’s account points to concrete outcomes: investor interest channelled into dozens of businesses and substantial cumulative fundraising. Those metrics are likely to be welcomed by policymakers seeking evidence that targeted support for clusters can yield commercial growth and jobs.
Key facts at a glance
- Established: 2012 (partnership between GSK, the Wellcome Trust and the UK Government)
- Companies on campus: more than 45
- Investment raised by campus companies: over £4 billion
- Local regeneration fund: £1 billion for Stevenage town
| Metric | Value |
|---|---|
| Companies at SBC | More than 45 |
| Capital secured by campus firms | Over £4 billion |
| Stevenage regeneration | £1 billion |
For the UK’s life‑sciences strategy, maintaining relationships between large pharmaceutical companies and innovation campuses remains a practical lever for economic development. SBC said it will continue to work with partners in Cambridge, London and beyond to accelerate innovation and expand collaborations that can support its companies and the wider region.
Local officials and SBC leaders also acknowledged the human impact of corporate decisions. Councillors and executives signalled support for staff and families affected by GSK’s moves while emphasising their determination to protect and grow the ecosystem that has formed in Stevenage.
As ministers and investors weigh future support for UK research and development, the Stevenage example provides a measurable case of how campus‑style initiatives can attract follow‑on funding and align regional regeneration with national industrial priorities.
